Page 11 - ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
These Are The Top Priorities Challenges For New CDER Director Patrizia Cavazzoni MD
clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.
These Are The Top Priorities Challenges For New CDER Director Patrizia Cavazzoni MD
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, everyone, and welcome to Pfizer s second-quarter 2021 earnings conference call. Today s call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investment relations officer.
Please go ahead, sir.
Senior Vice President and Chief Investment Relations Officer
Thank you, Sylvia. Good morning. It s my pleasure to be welcoming you to Pfizer s second-quarter earnings call for the first time as the head of investor relations at Pfizer. I m joined today by Dr.
Albert Bourla, our chairman and CEO; Frank D Amelio, our CFO; Mikael Dolsten, president of worldwide research and development and medical; Angela Hwang, group president, Pfizer Biopharmaceuticals Group; John Young, our chief business officer; and Doug Lankler, general counsel. We ll begin the call with remarks by Albert, followed by a pipeline update from Mikael, and Frank will then give you his thoughts on the numbers and our updated guidance b
COVID-19 vaccines don t have full authorization Expert explains why
therolladailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from therolladailynews.com Daily Mail and Mail on Sunday newspapers.
Lumateperone is a butyrophenone atypical antipsychotic developed by
Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the schizophrenia treatment, and currently in development for Bipolar Depression and other neurological indications. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Applications (sNDAs) for lumateperone to treat depressive episodes associated with bipolar I or II disorder, as monotherapy and as adjunctive therapy with lithium or valproate. If approved, CAPLYTA has the potential to be a vital medicine for a broad group of patients suffering from these highly prevalent, chronic, complex conditions.
Ketamine Hydrochloride: NeuroRx, Inc.
NeuroRx has developed a sequential therapy comprising IV